<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747978</url>
  </required_header>
  <id_info>
    <org_study_id>CNO20164</org_study_id>
    <nct_id>NCT03747978</nct_id>
  </id_info>
  <brief_title>Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes</brief_title>
  <official_title>Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaounde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Yaounde 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yaounde Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a double-blinded randomized controlled trial of 24-hour blood pressure control in
      sub Saharan type 2 diabetes patients, newly diagnosed for hypertension. They were allocated
      to receive either a fixed combination of perindopril + amlodipine or perindopril + indapamide
      for 42 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blinded randomized controlled trial conducted at the National Obesity
      Center and the cardiology unit of the Yaoundé Central Hospital in Cameroon from October 2016
      to May 2017. Eligible patients were type 2 diabetes patients, newly diagnosed for
      hypertension (grade I or II) with confirmation on ambulatory BP monitoring (ABPM). Patients
      were either on lifestyle modification alone or on a stable anti-diabetic treatment for the
      past three months, aged 25-65 years naïve to any anti-hypertensive treatment, who provided
      their written informed consent. Participants were assigned to receive as anti-hypertensive
      treatment perindopril-amlodipine once daily or perindopril-indapamide at the same frequency.
      The two groups were followed up and monitored for sixth weeks and patients did not take any
      additional treatment with BP modifying properties.

      The primary outcome was the relative change in circadian blood pressure profile between the
      two groups after six weeks of treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">May 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind head to head trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour blood pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in average 24-hour blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>night blood pressure dip</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in average night time blood pressure drop</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Perindopril and Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perindopril-Indapamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril and Amlodipine</intervention_name>
    <description>Fixed combination of Perindopril 5mg and Amlodipine 5mg</description>
    <arm_group_label>Perindopril and Amlodipine</arm_group_label>
    <other_name>Coveram5/5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril-indapamide</intervention_name>
    <description>Perindopril 5mg and Indapamide 1.25mg</description>
    <arm_group_label>Perindopril-Indapamide</arm_group_label>
    <other_name>Bipreterax5/1.25</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult diabetes patients aged between 25-65 years,

          -  with grade I or grade II (WHO classification) hypertension on the clinical measure,
             confirmed by ABPM

          -  naïve to any anti-hypertensive treatment

          -  written informed consent.

        Exclusion Criteria:

          -  Patients with grade III hypertension (WHO classification) were classified as
             hypertensive emergency,

          -  estimated creatinine clearance ˂30ml/min/1.73m2 (using Modified Diet in Renal Diseases
             formula)

          -  alanine transaminase (ALT)≥ 3 normal

          -  any contraindication to study drugs (hypersensitivity)

          -  pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Sobngwi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yaounde Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Obesity Centre, Yaounde Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <state>Centre</state>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 18, 2018</last_update_submitted>
  <last_update_submitted_qc>November 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yaounde Central Hospital</investigator_affiliation>
    <investigator_full_name>Sobngwi Eugene</investigator_full_name>
    <investigator_title>Medical Advisor</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>hypertension</keyword>
  <keyword>blacks</keyword>
  <keyword>Africa</keyword>
  <keyword>ACE inhibitor</keyword>
  <keyword>Calcium channel blocker</keyword>
  <keyword>Diuretic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Indapamide</mesh_term>
    <mesh_term>Indapamide, perindopril drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

